Reduction of the cetrorelix dose in a multiple-dose antagonist protocol and its impact on pregnancy rate and affordability: A randomized controlled multicenter study-Reference-Cited by-同舟云学术

Reduction of the cetrorelix dose in a multiple-dose antagonist protocol and its impact on pregnancy rate and affordability: A randomized controlled multicenter study

Published:2017 Issue:4 Volume:44 Page:232
ISSN:2233-8233
Container-title:Clinical and Experimental Reproductive Medicine
language:en
Short-container-title:Clin Exp Reprod Med

Author:

Dawood Ayman S.¹,Algergawy Adel¹,Elhalwagy Ahmed¹

Affiliation:

1. Department of Obstetrics and Gynaecology, Faculty of Medicine, Tanta University, Tanta, Egypt.

Publisher

The Korean Society for Reproductive Medicine

Subject

Reproductive Medicine

Link

https://synapse.koreamed.org/pdf/10.5653/cerm.2017.44.4.232

Reference18 articles.

1. Preventing ovarian hyperstimulation syndrome: guidance for the clinician

2. Are GnRH antagonists comparable to agonists for use in IVF?

3. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation

4. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group

5. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin)

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel orally active gonadotropin‐releasing hormone antagonist, relugolix, is a potential substitute for injectable GnRH antagonists in controlled ovarian stimulation in assisted reproductive technology;Reproductive Medicine and Biology;2021-11-12

2. Effect of oral Utrogestan in comparison with Cetrotide on preventing luteinizing hormone surge in IVF cycles: A randomized controlled trial;International Journal of Reproductive BioMedicine (IJRM);2020-01-26